GARDP North America appoints new Executive Director

GARDP North America (GARDP NA) is pleased to announce the appointment of Andrew Betts as its new Executive Director.


In his new role as Executive Director of GARDP NA, Mr Betts will build the presence and profile of GARDP NA in tackling antibiotic resistance, one of the biggest health threats in North America and globally.


“I am thrilled to be joining a young, vibrant, impactful, and fast-growing organization like GARDP North America,” said Andy Betts. “The potential to make vast strides of progress at a pivotal time of need and with much global attention is very exciting.”


Mr Betts will be responsible for managing the operations of GARDP NA, which was founded in 2021 to accelerate the development and availability of much-needed antibiotic treatments. In May 2022, GARDP NA received 501(c)(3) status as a public charity from the US Internal Revenue Service.


In his new role, Mr Betts will focus on implementing a fundraising and visibility strategy to secure funding partnerships from both public and private sources.  He will report to the GARDP NA Board and work closely with the GARDP network with the common goal of raising awareness and developing solutions to tackle antibiotic resistance worldwide.


GARDP’s projects target bacteria that have been labelled “priority pathogens” in urgent need of new treatments by the US Centers for Disease Control and Prevention as well as the World Health Organization.


“We are delighted to have Andy join GARDP North America as its new Executive Director,” said Dr Sara Cosgrove, Board Chair of GARDP North America and Professor of Medicine in the Division of Infectious Diseases at Johns Hopkins University. “We look forward to working closely with Andy to help build GARDP North America’s profile as a key player in accelerating antibiotic innovation and access.”


Mr Betts joins GARDP NA from the Polycystic Kidney Disease (PKD) Foundation based in Missouri (US), where he served as its President and CEO. He was instrumental in helping to secure the first US-approved treatment for a vastly unknown disease, and raised over $70M. Prior to this role, Mr Betts served as the Executive Director for Development at The Salvation Army, Kansas & Missouri.


Drug-resistant bacteria can infect anyone, anywhere. An estimated 2.8 million drug-resistant infections occur in the US each year. New treatments are urgently needed to fight antibiotic resistance.


About GARDP North America


Founded in 2021, GARDP NA, registered under the legal name GARDP North America Inc., drives innovative solutions to antibiotic resistance, one of the biggest health threats in North America and globally. As a member of the Global Antibiotic Research and Development Partnership’s network, GARDP NA pursues the common goal of accelerating the development and availability of much-needed antibiotic treatments. GARDP NA operates    independently with its own Board.


For more information about GARDP North America, please visit